Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of AR1001 in early Alzheimer's disease
NL-OMON60927Phase 3Active, not recruiting
- Sponsor
- AriBio
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing AR1001 with Placebo (2 arms). Primary endpoint: Change in CDR-SB. Started Jul 2024; status: active, not recruiting.
02
Drugs
mirodenafil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60927.